Drugs / BPX-601
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07543055 | Jul 2026 → Feb 2030 expected | prostate cancer | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT02744287 | Nov 2016 → Mar 2023 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPX-601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02744287 ↗ |
| Action | Deplete | “How well BPX-601 may work to destroy prostate cancer” NCT07543055 ↗ |
| Modality | Cell therapy | “Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain” NCT02744287 ↗ |
| Route | Intravenous | “Participants with advanced prostate cancer will receive an intravenous infusion of BPX-601” NCT02744287 ↗ |
| Target | PSCA | “Participants' T cells are modified to recognize and target the PSCA tumor marker on cancer cells.” NCT02744287 ↗ |